Home

TLDR Biotech

The top stories in biotech & pharma, straight to your inbox in only one email.
Trusted by 3000+ biotech and pharma professionals.

Comprehensive daily coverage of the biotech and pharma industry, straight to your inbox.

TLDR Biotech

The Latest Biotech & Pharma Updates

Biotech & Pharma Updates | August 6, 2026

Aug 6, 2026

•

3 min read

Biotech & Pharma Updates | August 6, 2026

🧬 FDA approves Moderna's mFLUVISA, first mRNA-based flu vaccine, for seasonal influenza prevention in adults 50 and older, LifeMine Therapeutics raises $263M in venture financings, advancing novel organ transplant treatment, Schrödinger expands Bristol Myers Squibb partnership with large-scale Bunsen AI co-scientist deployment

Christian Cuchapin, +1

Biotech & Pharma Updates | August 5, 2026

Aug 5, 2026

•

3 min read

Biotech & Pharma Updates | August 5, 2026

🧬 Eli Lilly posts record $23B Q2 revenue, driven by Mounjaro and Zepbound despite slower Foundayo launch, Icon, Anthropic partner to deploy Claude AI into clinical trials via multi-year collaboration, Gilead Sciences' HIV prevention franchise surpasses $1B quarterly sales, raises full-year HIV growth guidance

Christian Cuchapin, +1

Biotech & Pharma Updates | August 4, 2026

Aug 4, 2026

•

3 min read

Biotech & Pharma Updates | August 4, 2026

🧬 Otsuka's Voyxact (sibeprenlimab) stabilizes kidney function decline to normal levels in Ph3 immunoglobulin A nephropathy trial, Pathos AI, AstraZeneca, Jiangsu Alphamab Biopharmaceuticals ink dual breast cancer deals, $125M upfront, $2.093B milestones, Merck & Co. raises 2026 sales guidance to $67.3B as Keytruda, Winrevair, and Lipfendra drive growth

Christian Cuchapin, +1

Biotech & Pharma Updates | August 3, 2026

Aug 3, 2026

•

3 min read

Biotech & Pharma Updates | August 3, 2026

🧬 Supernus Pharmaceuticals, Indivior Pharmaceuticals merge in all-stock deal, creating $2.2B CNS company with 11 approved drugs, Novartis' Pluvicto (lutetium vipivotide tetraxetan) wins FDA approval for PSMA-positive metastatic hormone-sensitive prostate cancer label expansion, AstraZeneca, Bristol Myers Squibb reportedly in early-stage merger talks valuing combined entity at $400B

Christian Cuchapin, +1

Biotech & Pharma Updates | July 31, 2026

Jul 31, 2026

•

3 min read

Biotech & Pharma Updates | July 31, 2026

🧬 Replimune's (vusolimogene oderparepvec) wins positive adcomm vote for advanced melanoma in Ph1/2 combination trial, AstraZeneca, Daiichi Sankyo's Datroway (datopotamab deruxtecan) gains EU approval for first-line unresectable or metastatic triple-negative breast cancer based on Ph3 data, Regeneron posts biggest quarterly revenue growth since pandemic on booming Dupixent sales

Christian Cuchapin, +1

Biotech & Pharma Updates | July 30, 2026

Jul 30, 2026

•

3 min read

Biotech & Pharma Updates | July 30, 2026

🧬 Johnson & Johnson pays Sail Biomedicines $785M upfront, option to acquire for $2.58B in in vivo CAR-T deal, Eli Lilly, Resilience commit $750M to boost US diabetes and obesity medicine production, Sanofi raises 2026 outlook after Dupixent quarterly sales surpass €5B ($5.73B) milestone

Christian Cuchapin, +1

Biotech & Pharma Updates | July 29, 2026

Jul 29, 2026

•

3 min read

Biotech & Pharma Updates | July 29, 2026

🧬 Biogen flips 2026 revenue guidance to growth after Apellis Pharmaceuticals acquisition and strong new drug sales, AbbVie's Rinvoq (upadacitinib) earns dual EU approvals for non-segmental vitiligo and severe alopecia areata via Ph3 data, Caldera Therapeutics reverse merges with Synlogic, secures $278M financing to advance IBD bispecific antibody

Christian Cuchapin, +1

Biotech & Pharma Updates | July 28, 2026

Jul 28, 2026

•

3 min read

Biotech & Pharma Updates | July 28, 2026

🧬 GSK launches three-year restructuring targeting $2.5B annual cost savings by 2029 to fund pipeline growth, GSK to establish 300,000 sq ft flagship R&D centre at Cambridge Biomedical Campus, investing £400M ($531.6M), Atea Pharmaceuticals' (bemnifosbuvir/ruzasvir) matches Gilead's Epclusa in Ph3 trial for hepatitis C

Christian Cuchapin, +1

Biotech & Pharma Updates | July 27, 2026

Jul 27, 2026

•

3 min read

Biotech & Pharma Updates | July 27, 2026

🧬 Argenx acquires Forte Biosciences for $2.2B, gaining phase 2-stage vitiligo and celiac disease drug FB102, FDA approves Otsuka's Simtriyo (centanafadine), first norepinephrine-dopamine-serotonin reuptake inhibitor for attention-deficit hyperactivity disorder, AstraZeneca reaffirms $80B revenue target despite eplontersen trial failure and mixed pipeline results

Christian Cuchapin, +1

...

The Latest Biotech & Pharma Updates

Biotech & Pharma Updates | August 6, 2026

Biotech & Pharma Updates | August 5, 2026

Biotech & Pharma Updates | August 4, 2026

Biotech & Pharma Updates | August 3, 2026

Biotech & Pharma Updates | July 31, 2026

Biotech & Pharma Updates | July 30, 2026

Biotech & Pharma Updates | July 29, 2026

Biotech & Pharma Updates | July 28, 2026

Biotech & Pharma Updates | July 27, 2026

TLDR Biotech

FAQ

Media Partners